6BVD image
Deposition Date 2017-12-12
Release Date 2018-05-09
Last Version Date 2023-10-04
Entry Detail
PDB ID:
6BVD
Keywords:
Title:
Structure of Botulinum Neurotoxin Serotype HA Light Chain
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.09 Å
R-Value Free:
0.19
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Light Chain
Chain IDs:A, B
Chain Length:436
Number of Molecules:2
Biological Source:Clostridium botulinum
Primary Citation
Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Pathog Dis 76 ? ? (2018)
PMID: 29688327 DOI: 10.1093/femspd/fty044

Abstact

The extreme toxicity of botulinum neurotoxins (BoNTs) relies on their specific cleavage of SNARE proteins, which eventually leads to muscle paralysis. One newly identified mosaic toxin, BoNT/HA (aka H or FA), cleaves VAMP-2 at a unique position between residues L54 and E55, but the molecular basis underlying VAMP-2 recognition of BoNT/HA remains poorly characterized. Here, we report a ∼2.09 Å resolution crystal structure of the light chain protease domain of BoNT/HA (LC/HA). Structural comparison between LC/HA and LC of BoNT/F1 (LC/F1) reveals distinctive hydrophobic and electrostatic features near the active sites, which may explain their different VAMP-2 cleavage sites. When compared to BoNT/F5 that cleaves VAMP-2 at the same site as BoNT/HA, LC/HA displays higher affinity for VAMP-2, which could be caused by their different surface charge properties surrounding a VAMP-2 exosite-binding cleft. Furthermore, systematic mutagenesis studies on VAMP-2 and structural modeling demonstrate that residues R47 to K59 spanning the cleavage site in VAMP-2 may adopt a novel extended conformation when interacting with LC/HA and LC/F5. Taken together, our structure provides new insights into substrate recognition of BoNT/HA and paves the way for rational design of small molecule or peptide inhibitors against LC/HA.

Legend

Protein

Chemical

Disease

Primary Citation of related structures